Post-earnings recap
Reported
Wed, Nov 6, 2024
EPS actual
$-1.83
EPS est.
$-0.61
EPS surprise
-200.99%
1-day move
+0.83%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Soleno Therapeutics is facing significant challenges, particularly reflected in the EPS miss. Despite this, the stock saw a slight increase of 0.83%, which may suggest that investors are optimistic about the company's long-term strategy. The lack of revenue data and guidance leaves uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.83 | N/A | -200.99% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance but remains committed to their long-term goals. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term strategies despite current setbacks.